Published in Nat Rev Gastroenterol Hepatol on May 12, 2015
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy (2016) 0.84
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (2016) 0.83
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med (2016) 0.80
Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol (2016) 0.80
From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol (2016) 0.78
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. PLoS One (2016) 0.77
British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut (2017) 0.76
CT-Colonography vs. Colonoscopy for Detection of High-Risk Sessile Serrated Polyps. Am J Gastroenterol (2016) 0.76
Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women. Int J Cancer (2016) 0.75
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther (2017) 0.75
Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps: clinical implication for improved colon surveillance. Oncotarget (2016) 0.75
Colorectal cancer anatomic distribution patterns remain the same after sessile serrated adenoma/polyp considered cancer precursor: a 9-year comparison study from community-based endoscopy centers. J Gastrointest Oncol (2016) 0.75
Implementation of a program to improve the quality of colonoscopy increases the neoplasia detection rate: a prospective study. Endosc Int Open (2016) 0.75
Sessile Serrated Adenomas: How to Detect, Characterize and Resect. Gut Liver (2017) 0.75
Early detection: the impact of genomics. Virchows Arch (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med (1993) 21.18
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med (2012) 16.55
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
The evolution of cancer of the colon and rectum. Cancer (1975) 9.05
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 7.16
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J (2000) 6.55
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology (2010) 4.25
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy (2013) 4.03
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut (2009) 3.34
High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology (2006) 3.24
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol (1999) 2.78
Update on the serrated pathway to colorectal carcinoma. Hum Pathol (2010) 2.78
The risk of metachronous neoplasia in patients with serrated adenoma. Am J Clin Pathol (2005) 2.71
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol (2006) 2.55
Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. Clin Gastroenterol Hepatol (2013) 2.37
Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol (2010) 2.34
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res (2003) 2.27
Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol (2010) 2.26
Microsatellite instability in interval colon cancers. Gastroenterology (2006) 2.23
CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol (2009) 2.17
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00
Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut (2000) 1.95
Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell (2010) 1.93
Differences in proximal serrated polyp detection among endoscopists are associated with variability in withdrawal time. Gastrointest Endosc (2013) 1.87
Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol (2003) 1.82
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology (2013) 1.73
BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol (2004) 1.71
Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol Clin North Am (2008) 1.65
Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy (2013) 1.58
Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol (2002) 1.56
Nature and significance of hyperplastic polyps of the human colon. Arch Pathol (1970) 1.53
Long-term risk of colorectal cancer in individuals with serrated polyps. Gut (2014) 1.52
Structure and significance of metaplastic nodules in the rectal mucosa. J Clin Pathol (1968) 1.51
BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2012) 1.48
Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol (2009) 1.47
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med (2014) 1.47
Colorectal cancer epigenetics: complex simplicity. J Clin Oncol (2011) 1.47
Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res (2013) 1.42
Molecular classification and genetic pathways in hyperplastic polyposis syndrome. J Pathol (2007) 1.38
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med (2010) 1.36
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell (2013) 1.35
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34
Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. Am J Surg Pathol (2010) 1.33
Metaplastic polyps and polyposis of the colorectum. Histopathology (1980) 1.31
Relation between metaplastic polyp and carcinoma of the colorectum. Lancet (1983) 1.29
Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.27
Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer (2008) 1.27
Hyperplastic polyposis and the risk of colorectal cancer. Dis Colon Rectum (2004) 1.25
Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol (2011) 1.23
Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. Dig Dis Sci (2008) 1.20
Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol (2011) 1.20
Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol (2012) 1.18
Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy (2006) 1.16
A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. Am J Pathol (2011) 1.16
Molecular differences between sporadic serrated and conventional colorectal adenomas. Clin Cancer Res (2004) 1.16
Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps)-proposal for diagnostic criteria. Virchows Arch (2010) 1.14
Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. Am J Gastroenterol (2004) 1.14
Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res (2012) 1.12
Adenomatous and carcinomatous changes within hyperplastic colonic epithelium. Dis Colon Rectum (1979) 1.12
Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology (2009) 1.11
Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc (2014) 1.07
Serrated polyposis: rapid and relentless development of colorectal neoplasia. Gut (2012) 1.07
CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med (2008) 1.03
Outcomes of a 5-year follow-up of patients with sessile serrated adenomas. Scand J Gastroenterol (2012) 1.00
The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol Cell (2014) 1.00
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis (2013) 0.98
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One (2014) 0.97
Critical appraisal of the diagnosis of the sessile serrated adenoma. Am J Surg Pathol (2014) 0.97
Risk factors for serrated polyps of the colorectum. Dig Dis Sci (2014) 0.96
Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res (2014) 0.95
A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol (2014) 0.93
CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol (2007) 0.92
Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer. Cancer Epidemiol (2013) 0.92
Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum. Am J Surg Pathol (2014) 0.90
Endoscopic appearance of serrated adenomas in the colon. Endoscopy (2005) 0.89
Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod Pathol (2014) 0.88
Adenocarcinoma occurring in a hyperplastic (metaplastic) polyp of the colon. Endoscopy (1982) 0.86
Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions. Virchows Arch (2011) 0.86
Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. Gastroenterology (2014) 0.85
The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort. Gastroenterol Res Pract (2014) 0.84
Endoscopic characterization of sessile serrated adenomas/polyps with and without dysplasia. Endoscopy (2014) 0.82
Interval colorectal cancers: what and why. Curr Gastroenterol Rep (2014) 0.82
Evaluation of methylation of MGMT (O⁶-methylguanine-DNA methyltransferase) gene promoter in sporadic colorectal cancer. DNA Cell Biol (2013) 0.80
Sessile serrated adenomas/polyps with cytologic dysplasia: a triple threat for interval cancer. Gastrointest Endosc (2014) 0.79